Sales fell year over year, with their U.S. domestic business particularly weak. On a segment basis, the company’s pharmaceuticals and consumer sales both fell, yet medical devices and diagnostics rose 2.3%.
Overall, the company eked out year over year EPS growth mostly due to about $250 million less in research expense plus other cost control.
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.